Lilly claims partial victory for Alzheimer's drug
Top-line results show some hope for treatment even though a research goal was missed.
"We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline," said John C. Lechleiter, chief executive officer of Lilly. "We intend to discuss these data with regulatory authorities to gain their insights on potential next steps."
Shares of Lilly jumped 4% to $44 in trading Friday morning, though the gains were pared to 2.55% around noon.
However, some analysts cautioned that the drug still has a way to go before being approved.
"Basically the odds of approval just went up from (about) 10% to maybe 20 to 30%," ISI Group analyst Mark Schoenebaum says. He calls chances for the drug's success "still high risk" but notes the study results are much better than expected.
The data will be very controversial, he adds. Had the drug been shown to clearly meet its study goals, Lilly's stock might have jumped 50%, the analyst says. On the other hand, the stock was expected to drop on failure, even though expectations for a positive result were low.
Sentiment toward Lilly's drug soured after a similar treatment being developed by Pfizer (PFE), Johnson & Johnson (JNJ) and Elan (ELN) failed in studies. The disappointing results prompted those companies to pull the plug on their clinical program earlier this month.
Like other big drug companies, Lilly needs to replace sales of big products that have lost or are losing patent protection, opening them to generic competition.
More from Minyanville
- Are High-Yield Bonds in a Bubble?
- Stock Alert: Three Long, Three Short for August 24
- Does Twitter Really Think It Can Control Its Users?
Copyright © 2014 Microsoft. All rights reserved.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.